Oncologists Urged to Help Obese Breast Cancer Patients Manage Weight

OncologyLive, August 2015, Volume 16, Issue 8

There is clear evidence that obesity at the time of diagnosis of operable breast cancer is associated with an increased risk of distant recurrence, specifically for HR–positive, HER2-negative disease, and oncologists should consider helping patients better manage their weight as part of their treatment plans.

Joseph A. Sparano, MD

There is clear evidence that obesity at the time of diagnosis of operable breast cancer is associated with an increased risk of distant recurrence, specifically for hormone receptor (HR)—positive, HER2-negative disease, and oncologists should consider helping patients better manage their weight as part of their treatment plans, according to Joseph A. Sparano, MD.

These were among the conclusions that Sparano drew during a presentation at the 14th Annual International Congress on the Future of Breast Cancer® that Physicians’ Education Resource (PER®) hosted in Huntington Beach, California, July 16-19.

Sparano, who has studied the impact of obesity on patients with breast cancer extensively, is associate director of clinical research for Albert Einstein Cancer Center and chief of the section of breast medical oncology at the Montefiore Einstein Center for Cancer Care in New York.

Obesity is conventionally defined as a body mass index (BMI) of >30 kg/m2. Sparano also noted that women with a BMI in the overweight range of 25 to 30 kg/m2 appear to have an increased risk of recurrence compared with women who have a normal BMI of 18.5 to 25 kg/m2 at diagnosis.

Since obesity is a major health problem in the United States, it is important for physicians to incorporate weight issues into disease analysis and treatment regimens, Sparano said. “More than a third of adults—72 million individuals—are obese. The obesity rates have increased two-fold in adults and three-fold in children since 1980,” he noted. Oncology researchers are starting to focus on ways to address the impact of excess weight for women with breast cancer. The Alliance for Clinical Trials in Oncology is about to initiate a randomized trial in women who have stage II/III breast cancer diagnosed within 12 months, are overweight or obese, and have completed their adjuvant systemic chemotherapy and radiation. The women will be randomized to a health and education intervention with a 2-year telephone-based weight loss intervention, Sparano said.

Sparano advised that physicians take steps now to help patients with their weight, such as recommending dietary and lifestyle interventions, even though such guidance is “not normally within the scope of activities of medical oncologists.”

The interventions he advocated included a weight management program modeled after the Diabetes Prevention Project that has been shown to significantly reduce the risk of developing adult onset diabetes in obese patients; it includes caloric restrictions and exercising at least 2½ hours per week, or about 30 minutes 5 days per week. Sparano cited a study published in the Journal of the American Medical Association on July 15 indicating that exercise of 5 hours a week was even more effective in reducing adipose tissue.1

Obesity a Factor in Poorer Outcomes

A number of factors can influence outcomes and treatment decisions in patients who are obese, Sparano said, including differing disease characteristics, comorbidities, and differences in adjuvant therapy administration.

“It is important that chemotherapy dosing be based on the actual weight and not empirically reduced,” he said. “There is clear evidence that capping chemotherapy doses is associated with a higher risk of recurrence, and is not effective in reducing chemotherapy-associated toxicity. In fact, an ASCO expert panel has specifically recommended weight-based dosing irrespective of BMI.”2

Given the multiple factors that could potentially contribute to worse outcomes in patients with breast cancer who are obese, Sparano and his fellow researchers attempted to disentangle these factors by taking a fresh look at the E1199 trial, which evaluated taxane doses and schedules for 4950 patients with breast cancer.3

“Our objective was to determine the relationship between BMI, clinical characteristics, and clinical outcomes,” defined according to breast cancer subtype as hormone receptor (HR)—positive, HER2 negative, HER2 positive, and triple negative, said Sparano. Patients were relatively healthy and were required to have normal cardiac, liver, and pulmonary function.

“When we looked at the characteristics of the obese versus nonobese subjects, we found that the obesity was associated with postmenopausal status, older age, black race, and somewhat greater use of breast conservation therapy. We found no significant differences in other characteristics, such as median tumor size, nodal status, estrogen receptor, progesterone receptor [PR], or the type of endocrine therapy administered,” Sparano said.

Drugs administered included doxorubicin, cyclophosphamide, docetaxel, and paclitaxel, Sparano said, and were given on weight-based dosing. The drug delivery and toxicity patterns were similar for all drugs except for paclitaxel, where there were marginally more dose reductions and neutropenia among the obese group. There were also no substantive differences in administration of or compliance with adjuvant endocrine therapy.

Despite the lack of any substantial differences in disease characteristics at presentation or in chemotherapy delivery, Sparano noted that in the HR-positive, HER2-negative group, obese patients had worse outcomes, including a 23% higher risk of recurrence, contralateral cancer or another cancer or death, and a nearly 50% higher risk for death, both of which were highly statistically significant. “We didn’t see this in patients with HER2-positive or the triple-negative disease,” Sparano said.

Additional studies were reviewed to confirm these findings, and again, Sparano and his fellow researchers found worse outcomes for both disease-free survival and overall survival among patients who were obese.

The association between obesity and poorer outcomes persisted in a long-term follow-up analysis of the E1199 study that Sparano and colleagues published earlier this year.4 After a median follow-up of 12.1 years, the strong association between obesity and poor outcomes specifically in ER-positive, HER2-negative disease persisted.

Moreover, Sparano found that obesity was associated with an elevated risk of recurrence for approximately 3 to 8 years after diagnosis. “This raises the possibility that there may be sufficient lead time between diagnosis and recurrence to permit currently recommended dietary and lifestyle interventions to have a significant impact in reducing the risk of recurrence,” the researchers wrote.4

During his presentation, Sparano noted that the association between obesity and comparatively poor outcomes also was found in a study reported at the 2014 ASCO Annual Meeting.5 The analysis of data from 70 clinical trials found that among 60,000 women with estrogen receptor (ER)—positive breast cancer adjusted for tumor characteristics, premenopausal obese women had a 34% increase in the risk of recurrence and death compared with women of normal weight.

By contrast, postmenopausal women in the obese and nonobese categories showed very little difference in recurrence likelihood. The same study found no association between weight and outcomes among 20,000 women with ER-negative disease.

Factors That Drive Recurrence

Factors that may be associated with adipose tissue and are driving breast cancer recurrence include metabolic alterations such as higher estrogen, insulin, leptin (important for appetite and energy homeostasis), and lower levels of adiponectin (important for glucose regulation and lipid metabolism). Also, raised levels of inflammatory cytokines, such as IL-6 and NF-kappaB, can affect breast cancer physiology, Sparano said.

He noted this was revealed in a 2012 study published in Cancer Discovery, which indicated that breast inflammation, typical of obese women, leads to higher production of the enzyme aromatase, which fuels estrogen production.6

“There is this link between adiposity, inflammation, and aromatase enzyme activity that could be contributing to some of these effects,” Sparano said. Another suspect in the roundup for causes of breast cancer recurrence in obese women is 27- hydroxycholesterol (27HC), a metabolite of cholesterol, which in cases of hypercholesterolemia is known to be a risk factor for ER-positive breast cancers and is also associated with resistance to endocrine therapies, Sparano said. A 2013 study concluded that “interfering with its conversion to 27HC may be a useful strategy to prevent and/or treat breast cancer.”7

“Other studies have shown a relationship between obesity and recurrence, and resistance to endocrine therapy,” Sparano said. This was demonstrated in an exploratory analysis of the ATAC trial, which indicated a significantly higher risk of recurrence over time for high-BMI, postmenopausal women who received anastrozole, tamoxifen, or a combination.8 The aromatase inhibitor anastrozole was compared with tamoxifen for 5 years in 4939 postmenopausal women with HR-positive localized breast cancer. Side effects and recurrences had restricted the success of standard adjuvant endocrine treatment. After the 9-year point, roughly 26% of patients with a BMI higher than 30 suffered recurrences, versus around 18% of women with a BMI less than 23.8

“If you look at the benefit of anastrozole versus tamoxifen stratified based on BMI, you see that it’s the lean women who seem to be deriving the greater benefit from an aromatase inhibitor compared with tamoxifen,” Sparano said. “This may be due to greater suppression of estrogen.”

Increases in activated growth factor-1 and insulin receptors are among the smoking guns in the search for recurrence factors, Sparano said. “We know that fasting insulin levels are higher— high fasting insulin levels even within the normal range are associated with higher breast cancer risk and risk of recurrence. There is this common theme here of these factors contributing not only to the risk of recurrence but the risk of developing breast cancer in the first place.”

Interventions That Help Patients

Recognizing that there is a definite link between obesity and breast cancer recurrence, efforts can be made to help patients lose weight, including pharmacologic, dietary, and lifestyle interventions, said Sparano.

A diabetes prevention project was successful in achieving a 7% average weight reduction in a population of high-risk individuals who were randomized to a lifestyle intervention that included a low fat diet and 150 minutes of exercise a week.9

Those patients did substantially better than others in the trial who received education plus placebo or education plus the anti-diabetic drug metformin. “The lifestyle change was effective at all ages, especially in patients over the age of 60,” Sparano said.

A hypothesis that metformin could reduce the risk of breast cancer has been tested in the MA.32 trial, whose full results have not been released yet. The trial targeted women with early-stage breast cancer who had completed adjuvant chemotherapy and were randomized to receive metformin for 5 years or a placebo. Although the main results are not out, a metabolic substudy has revealed that “significantly” greater reductions in weight, BMI, glucose, insulin levels, leptin, and C-reactive protein (levels of which rise in response to inflammation) were achieved in the metformin arm.10

Other trials involving low-fat diets have been promising in terms of weight loss, Sparano said, adding that the Mediterranean or low carbohydrate diet was more effective in achieving weight reduction than a low fat diet.

Inconsistent benefit has been seen for physical activity with regard to breast cancer prognosis, Sparano concluded, but added, “Probably, in order to maximize the effects and proven outcomes, one needs to increase physical activity and alter eating habits.”

References

  1. Friedenreich CM, Neilson HK, O’Reilly R, et al. Effects of a high vs moderate volume of aerobic exercise on adiposity outcomes in postmenopausal women: a randomized clinical trial [published online July 16, 2015]. JAMA Oncol. doi:10.1001/jamaoncol.2015.2239.
  2. Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline [published online April 2, 2012]. J Clin Oncol. 2012;30(13):1553-1561.
  3. Sparano JA, Wang M, Zhao F, et al. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer [published online August 27, 2012]. Cancer. 2012;118(23):5937-5946.
  4. Sparano JA, Zhao F, Martino S, et al. Long-term follow-up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer [published online June 15, 2015]. J Clin Oncol. 2015;33(21):2353-2360.
  5. Pan H, Gray RG. Effect of obesity in premenopausal ER+ early breast cancer: EBCTCG data on 80,000 patients in 70 trials. J Clin Oncol. 2014;32(5s suppl; abstr 503).
  6. Subbaramaiah K, Morris PG, Zhou XK, et al. Increased levels of COX- 2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women [published online January 27, 2012]. Cancer Discov. 2012;2(4):356-365.
  7. Nelson ER, Wardell SE, Jasper JS, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013;342(6162):1094-1098.
  8. Sestak I, Distler W, Forbes JF, et al. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol. 2012;28(21):3411-3415.
  9. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.
  10. Goodwin PJ, Parulekar W, Gelmon KA, et al. Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC). J Clin Oncol. 2013;31(suppl; abstr 1033).